双歧杆菌三联活菌胶囊联合四联疗法根除幽门螺杆菌临床观察.docVIP

双歧杆菌三联活菌胶囊联合四联疗法根除幽门螺杆菌临床观察 　　【摘要】 目的 探讨双歧杆菌三联活菌胶囊联合四联疗法根除幽门螺杆菌治疗消化性溃疡的疗效及安全性。方法 122例合并幽门螺杆菌感染的消化性溃疡患者， 随机分为对照组和治疗组， 每组61例。对照组采用四联疗法治疗， 疗程10 d， 治疗组在对照组的基础上加用双歧杆菌三联活菌胶囊口服， 疗程10 d。停用四联药物后继续口服奥美拉唑肠溶胶囊， 胃溃疡服用6周， 十二指肠溃疡服用4周；治疗组继续服用双歧杆菌三联活菌胶囊10 d。最后在内镜下观察两组溃疡的愈合情况。结果 治疗组和对照组幽门螺杆菌根除率分别为91.8%、73.8%， 疗程结束后复查胃镜溃疡达瘢痕期两组分别为86.9%、67.2%， 两组比较差异均有统计学意义（P0.01）。两组上腹部不适、便秘发生率比较差异具有统计学意义（P0.01或P0.05）。结论 双歧杆菌三联活菌胶囊联合四联疗法治疗合并幽门螺杆菌感染的消化性溃疡， 镜下溃疡愈合情况明显优于单用四联疗法， 幽门螺杆菌的根除率明显提高， 且能减少应用抗生素的不良反应。 　　【关键词】 消化性溃疡；幽门螺杆菌；双歧杆菌三联活菌胶囊；四联疗法 　　DOI：10.14163/j.cnki.11-5547/r.2016.05.001 　　Clinical observation of bifidobacterium-triple viable capsule combined with quadruple therapy in eradication of helicobacter pylori YUAN Quan， XU Xiu-fen， LIU Gui-fang. Department of Gastroenterology， Shandong Weihai City Weihaiwei People’s Hospital， 264200， China 　　【Abstract】 Objective To investigate curative effect and safety by bifidobacterium-triple viable capsule combined with quadruple therapy in eradication of helicobacter pylori for treating peptic ulcer. Methods A total of 122 patients of helicobacter pylori complicated with peptic ulcer were randomly divided into control group and treatment group， with 61 cases in each group. The control group received quadruple therapy for 10 d， and the treatment group received additional bifidobacterium-triple viable capsule by oral administration for 10 d. After withdrawal of quadruple drugs， omeprazole enteric-coated capsule was given by oral administration for 6 weeks in gastric ulcer and 4 weeks in duodenal ulcer. The treatment group continuously received bifidobacterium-triple viable capsule for 10 d. Healing condition of the two groups was observed by endoscope. Results The treatment group and the control group had eradication rate of helicobacter pylori respectively as 91.8% and 73.8%. After treatment， cicatricial phase of ulcer by gastroscopy accounted for 86.9% and 67.2% respectively in the two groups. Their differences all had statistical significance （P 　　【K